We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Nathalie
MacDermott
nathalie.macdermott@kcl.ac.uk
Nathalie
MacDermott
nathalie.macdermott@kcl.ac.uk
Rebeca
Martinez
Rebeca.Martinez@gstt.nhs.uk
Provisional assignment of new diseases of uncertain etiologySymptoms and signs involving cognition, perception, emotional state and behaviour
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Long Covid is a heterogeneous, poorly understood condition described in both adults and children with a history of COVID-19. Estimates vary of proportions of children and young people (CYP) affected. Data from the Office of National Statistics estimates that 8% of CYP may experience symptoms beyond 12 weeks.A more conservative estimate suggests 1.8% of CYP may experience symptoms beyond two months, although this is in contrast to the CLoCK study which has demonstrated approximately 14% of CYP experience persistent symptoms at 3 months following confirmed COVID-19 when compared with their peers who tested negative for COVID-19. Several different underlying disease processes have been suggested. These include persistence of the SARS-COV2 virus in the body, a persistent inflammatory process triggered by the initial viral infection, and an autoimmune reaction, where the virus has triggered the person’s immune system to attack their own cells and organ systems. The focus of this research is on the neurological immune response that may occur following significant inflammation within the body. Patients who experienced marked inflammation within the body during or following COVID-19 often presented with multisystem inflammatory syndrome (PIMS-TS). These patients have been shown to have more neurological symptoms and signs during their acute illness and require longer to recover. As long COVID may be a persistent inflammatory process in the body, we would like to understand the possible role of this in the neurological and ‘brain fog’ symptoms experienced by children with long COVID.
We aim to recruit 80 CYP with long COVID from the pan-London post-COVID service to undergo in depth MRI imaging, clinical assessment and blood tests looking at immune function, to better understand the mechanism causing damage in long COVID. We will compare this with data from 20 children fully recovered from COVID-19 and a large group of healthy controls recruited pre-pandemic.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
- Under 10 years - 18 years of age and over - Require GA/sedation for MRI scanning - No confirmed diagnosis of COVID-19/Post COVID Syndrome/long COVID - Known MRI contraindications - Structural lesions prior to COVID-19 - Active or previous CNS autoimmune condition - History of systemic autoimmune condition
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Rebeca
Martinez
Rebeca.Martinez@gstt.nhs.uk
Nathalie
MacDermott
nathalie.macdermott@kcl.ac.uk
Nathalie
MacDermott
nathalie.macdermott@kcl.ac.uk
The study is sponsored by King's College London and funded by ACTION MEDICAL RESEARCH .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 60940
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
